Lilly to Present at J.P. Morgan Healthcare Conference

INDIANAPOLIS, Dec. 19, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will present at the 32nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2014. John C. Lechleiter, Ph.D., Lilly's chairman, president and chief executive officer will make a formal presentation from 2:30 p.m. to 2:55 p.m. PST.

A live audio webcast will be available on the Webcasts & Presentations section of Lilly's Investor website at http://investor.lilly.com/events.cfm . Subsequently, a replay of Dr. Lechleiter's presentation will be available on this same website for approximately 90 days.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.  Additional information about Lilly is available at www.lilly.com.  F-LLY

Refer to:    

(317) 276-5795 – Mark Taylor (Media)


(317) 655-6874 – Philip Johnson (Investors)

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )

SOURCE Eli Lilly and Company

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.